Boca Raton, Florida, US, April 16, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune ...

This milestone further strengthens Nexalin’s intellectual property portfolio and affirms the potential of its proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology, a non-invasive and ...